Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.60 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29422979 | 1.00 | CYP2A6 (0.60) | CYP2A6CYP3A4CYP2E1CYP2B6CYP2D6 | |
| Pyrazole SCHEMBL28013454 | 0.88 | CYP2A6 (0.49) | CYP2A6CYP3A4CYP2E1CYP2B6CYP2D6 | |
| SCHEMBL162771 | 0.80 | — | — | |
| Pyridine SCHEMBL28139351 | 0.79 | CYP3A4 (0.45) | CYP2A6CYP3A4CYP2E1CYP2B6CYP2D6 | |
| Hydrochloric Acid SCHEMBL6647002 | 0.78 | CYP2A6 (0.53) | CYP2A6CYP3A4CYP2E1CYP2B6CYP2D6 | |
| Hydrochloric Acid SCHEMBL28088469 | 0.78 | CYP2A6 (0.53) | CYP2A6CYP3A4CYP2E1CYP2B6CYP2D6 | |
| SCHEMBL8013084 | 0.78 | ATM (0.44) | CYP2A6CYP3A4CYP2E1CYP2B6CYP2D6 | |
| Pyridine SCHEMBL28547162 | 0.78 | CYP3A4 (0.44) | CYP2A6CYP3A4CYP2E1CYP2B6CYP2D6 | |
| SCHEMBL29827246 | 0.77 | CYP2A6 (0.53) | CYP2A6CYP3A4CYP2E1CYP2B6CYP2D6 | |
| SCHEMBL2457937 | 0.77 | CHRNB2 (0.67) | ALDH1A1KDM4ETP53MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939291-B2 | GRP94 selective inhibitors and uses thereof | UNIVERSITY OF KANSAS (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230391752-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | CHULALONGKORN UNIVERSITY (TH) | 2023-12-07 | — | — | US | disclosed |
| CN-110452243-B | Pyrrolopyrimidine derivative epidermal growth factor inhibitor and preparation method and application thereof | 药雅科技(上海)有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-114746090-A | Azaindole carboxamide compounds for the treatment of mycobacterial infections | 结核病药物开发全球联盟公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220024869-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF KANSAS | 2022-01-27 | — | — | US | disclosed |
| US-20220024869-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | UNIVERSITY OF KANSAS | 2022-01-27 | — | — | US | disclosed |
| US-20220008891-A1 | PROCESS FOR CONDITIONING METAL-ORGANIC FRAMEWORKS BY MEANS OF MEMBRANE FILTRATION | BASF SE (DE) | 2022-01-13 | — | — | US | disclosed |
| US-20210289832-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210213091-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| CN-101175747-A | Substituted N-arylpyrrolidines as selective androgen receptor modulators | LILLY CO ELI (US) | 2008-05-07 | — | — | CN | disclosed |
| US-20070072001-A1 | Luminescent device | CANON KABUSHIKI KAISHA (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072001-A1 | Luminescent device | CANON KABUSHIKI KAISHA (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20040198730-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1432699-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027101-A1 | SUBSTITUTED 3-PYRIDYL PYRROLES AND 3-PYRIDYL PYRAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027101-A1 | SUBSTITUTED 3-PYRIDYL PYRROLES AND 3-PYRIDYL PYRAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003022832-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-20 | — | — | WO | disclosed |
| EP-0103969-B1 | PRINTING INKS AND PRINTED SUBSTRATES | LAWRENCE, Peter Robin Broughton (GB) | 1986-10-29 | — | — | EP | disclosed |
| US-4574151-A | Amine salts and products containing them | Lawrence, Peter Robin Broughton (GB) | 1986-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198730-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | BRAF, ARAF, RAF1 | CYP2A6 3714/4885CYP3A4 3513/4885CYP2E1 2713/4885 |
| US-20230391752-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | GLS2, PYGL, CPS1 | CYP2A6 160/4885CYP3A4 34/4885CYP2E1 5/4885 |
| US-20210145818-A1 | COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF | CHRNA5, SLC18A3, CHRNA6 | CYP2A6 1222/4885CYP3A4 1962/4885CYP2E1 2509/4885 |
| US-11939291-B2 | GRP94 selective inhibitors and uses thereof | GRPR, HSP90B1, HSPE1 | CYP2A6 4220/4885CYP3A4 3988/4885CYP2E1 4348/4885 |
| US-20220024869-A1 | GRP94 SELECTIVE INHIBITORS AND USES THEREOF | GRPR, HSP90B1, HSPE1 | CYP2A6 4220/4885CYP3A4 3988/4885CYP2E1 4348/4885 |
| US-20220008891-A1 | PROCESS FOR CONDITIONING METAL-ORGANIC FRAMEWORKS BY MEANS OF MEMBRANE FILTRATION | CD69, OSTC, OGFR | CYP2A6 2798/4885CYP3A4 2853/4885CYP2E1 2183/4885 |
| US-20210213091-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | MGLL, LIPA, LAMP1 | CYP2A6 2861/4885CYP3A4 2893/4885CYP2E1 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.